Allergy Infusion: Xolair Is a Subcutaneous Injection, Not an IV Infusion
IMPORTANT DISAMBIGUATION: Allergy infusion is a misnomer. Searchers typically mean Xolair (omalizumab) — an anti-IgE biologic subcutaneous injection, NOT an IV infusion, despite patients recalling it as an 'infusion' because it is administered in a clinic under monitoring. There is no IV-infusion form of subcutaneous immunotherapy (SCIT). SCIT is a small 0.05-0.5 mL subcutaneous injection in the upper arm with a 26-27G needle per Cox 2011 PP3. Xolair was approved February 16, 2024 for IgE-mediated food allergy per OUtMATCH trial.
7 peer-reviewed sources
This page is about allergy infusion disambiguation: Xolair (omalizumab) is an anti-IgE biologic subcutaneous injection — NOT an IV infusion. There is no IV-infusion allergy immunotherapy product in the US. SCIT is a small subcutaneous shot in the upper arm, not an infusion.
Key facts
Across 2,897 patients treated with sublingual immunotherapy via telemedicine in 2026, no cases of anaphylaxis were reported — the safety difference that allows the sublingual route to be self-administered at home, unlike injections.
The essentials
Allergy infusion is one of the most consequential disambiguation pages in allergy medicine: searchers using this term are overwhelmingly NOT looking for subcutaneous immunotherapy (SCIT) — they are almost always looking for Xolair (omalizumab), the anti-IgE biologic monoclonal antibody.
The 'infusion' misconception arises from a specific patient experience: Xolair is administered subcutaneously (under the skin) in a clinic or physician's office, requires monitoring for the first three doses for 60 minutes per FDA REMS requirements (then 30 minutes), and is given by a healthcare professional from a vial — all features that patients associate with an 'infusion.' In reality, Xolair is a subcutaneous injection (SC, not IV), using a standard needle at subcutaneous depth — similar to SCIT injections. Some early pre-approval Xolair trials did use intravenous administration, which may also contribute to the 'infusion' mental model. But the FDA-approved route is subcutaneous.
For absolute clarity: there is NO IV-infusion form of allergen immunotherapy (SCIT) on the US market. SCIT is a small subcutaneous injection (0.05-0.5 mL volume, 26-27G needle, 5/8 inch length typical) into the upper outer arm per Cox 2011 PP3 (JACI 2011;127[1 Suppl]:S1-S55). It is not an infusion.
Xolair (omalizumab, Genentech/Novartis) is an anti-IgE monoclonal antibody (FDA-approved 2003 for moderate-to-severe persistent allergic asthma; expanded to chronic spontaneous urticaria, CRSwNP, and most recently IgE-mediated food allergy in patients aged 1 year and older on February 16, 2024, following the OUtMATCH trial published in NEJM 2024). Xolair binds free IgE in the bloodstream, reducing the IgE available to arm mast cells and basophils. It does NOT induce allergen-specific tolerance — symptoms return when Xolair is discontinued, and it must be taken indefinitely on a schedule individualized by your allergist.
The other biologic injections sometimes confused with an 'allergy infusion': Dupixent (dupilumab, anti-IL-4Rα, FDA-approved March 2017) and Tezspire (tezepelumab-ekko, anti-TSLP, FDA-approved December 17, 2021) are also subcutaneous injections administered on an individualized schedule and 4 weeks respectively.
Curex pairs at-home IgE testing with board-certified allergist review to identify allergen sensitization patterns — the same workup used to determine whether a patient is a candidate for SCIT, SLIT, or a biologic like Xolair. For eligible patients, the SCIT itself is delivered as one weekly self-administered shot at home with pricing confirmed in a current program quote — a personalized serum sterile-compounded to USP <797> standards, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand (still a small subcutaneous injection, never an infusion). On the safety of that self-administered model, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
How allergy shots retrain your immune system
SCIT (the actual 'allergy shot') works through a different mechanism than Xolair. SCIT uses allergen extract to retrain allergen-specific immunity through Treg cells and blocking IgG4 antibodies — producing durable post-treatment remission after the 3-5 year course. Xolair uses a monoclonal antibody to capture free IgE in the bloodstream, reducing mast-cell and basophil activation — effective for conditions driven by elevated IgE, but not inducing allergen-specific tolerance. The two are not interchangeable.
SCIT: subcutaneous allergen extract injection (0.05-0.5 mL, upper arm)
A small-volume injection of allergen extract into the subcutaneous tissue of the upper outer arm using a 26-27G needle. Build-up phase: weekly for 4-6 months. Maintenance: on a schedule individualized by your allergist for 3-5 years. 30-minute observation per Cox 2011 PP3. NOT an infusion.
Xolair (omalizumab): subcutaneous anti-IgE injection (not IV)
A subcutaneous injection of 75-375 mg omalizumab based on body weight and baseline IgE level, on a schedule individualized by your allergist in a clinic or physician's office. First three doses require 60-minute observation per FDA REMS. Not an IV infusion — same subcutaneous route as SCIT but with different extract (biologic antibody vs allergen).
The confusion: in-clinic monitoring creates 'infusion' mental model
Patients remember Xolair as an 'infusion' because it is given in a clinic by a professional, takes clinic time, and early clinical trials used IV administration. The FDA-approved route is SC. SCIT is also given in a clinic by a professional and also requires clinic monitoring — but neither is an infusion.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Xolair, Tezspire, and allergy shots work differently — compare them
If biologics haven't solved your allergies, Curex's at-home allergy shots target the root cause with clinician support.
See if you qualifyCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
Treatment options side by side
For patients trying to decide between the injectable allergy options — SCIT, Xolair, and other biologics — the key distinctions are mechanism, indication, and post-treatment durability.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots — NOT an infusion) | |||||
Xolair (omalizumab — SC injection, not IV infusion) | |||||
SLIT drops (for aeroallergen tolerance) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For aeroallergen tolerance without weekly clinic visits, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed by a board-certified allergist and self-administered as one weekly shot at home with pricing confirmed in a current program quote. The first injection from each new vial or concentration is supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector is confirmed on hand — a small subcutaneous shot, never an infusion, and no biologic injections required.
Join the waitlistFrequently asked questions
Is Xolair an infusion or injection?
Xolair (omalizumab) is a subcutaneous injection — not an intravenous infusion. The route of administration approved by the FDA is subcutaneous (under the skin), using a standard needle. Xolair is injected in a clinic or physician's office on a schedule individualized by your allergist, which creates the impression of an 'infusion visit,' but the actual drug delivery is subcutaneous. The first three doses require 60-minute observation; subsequent doses require 30-minute observation.
Is Tezspire (tezepelumab-ekko) an infusion or an injection?
Tezspire (tezepelumab-ekko) is a subcutaneous injection, not an IV infusion — the same delivery route used for Xolair and Dupixent. It is given on a clinician-set schedule for severe asthma, and the clinic time is largely the post-injection observation period rather than the injection itself. There is no IV-administered version of this drug.
Is there an IV allergy shot or infusion available?
No. There is no allergy immunotherapy injection administered intravenously in the United States. Subcutaneous immunotherapy (SCIT, the standard allergy shot) is delivered subcutaneously, not intravenously. Xolair, Dupixent, and Tezspire are all subcutaneous injections. Patients expecting an IV 'allergy infusion' in a clinical allergy setting are usually experiencing a misconception, most commonly about Xolair.
What is Xolair used for in allergy treatment?
Xolair (omalizumab) is approved by the FDA for several indications: moderate-to-severe persistent allergic asthma in patients 6 and older not controlled by inhaled corticosteroids; chronic spontaneous urticaria in patients 12 and older uncontrolled by antihistamines; chronic rhinosinusitis with nasal polyps as add-on therapy in adults; and IgE-mediated food allergy in patients 1 year and older. Dosing is based on total IgE level and body weight.
How does Xolair differ from allergy shots (SCIT)?
Xolair (omalizumab) and SCIT are fundamentally different interventions. SCIT uses allergen extract to train the immune system to tolerate specific allergens, producing durable post-treatment remission lasting years after stopping. Xolair captures free IgE antibodies in the bloodstream, reducing the IgE available to arm mast cells and basophils — effective for conditions driven by elevated IgE, but providing no allergen-specific tolerance. When Xolair is stopped, free IgE recovers and symptoms return. SCIT has a defined 3-5 year course; Xolair requires indefinite ongoing injections.
Can Xolair replace allergy shots for food allergy?
Xolair and SCIT are indicated for different conditions and cannot replace each other in most situations. SCIT (allergy shots) is not a standard treatment for food allergies — oral immunotherapy is the immunotherapy approach for food allergy, and SCIT for food allergy was largely abandoned decades ago after a fatal reaction in an early trial. Xolair is an approved option for IgE-mediated food allergy for patients who need broad multi-food protection. For aeroallergen allergy (pollens, dust mite, dander), SCIT or SLIT remains the disease-modifying standard.
What happens during a Xolair injection visit?
A Xolair injection visit involves a subcutaneous injection of omalizumab, calculated based on body weight and baseline total IgE level, administered in a physician's office or clinic. For the first three doses, 60-minute observation is required after injection because of rare but serious adverse reactions. After the first three doses, 30-minute observation is standard. Each injection itself takes only a few minutes; the clinic time is dominated by the observation period.
Related Articles
Allergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shot for Dog Allergies | Curex Human SCIT Guide
Yes, there is an allergy shot for humans allergic to dogs — but dog SCIT evidence is 'poor and conflicting.' 16.5% of patients may skip shots if Can f 5-monosensitized.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read moreAllergy Medicine Injection: SCIT vs Biologics vs Steroids | Curex
Allergy medicine injections include SCIT (allergen extract — not a drug), Xolair, Dupixent, and depot steroids. SCIT is the only option with 4-yr post-treatment remission per NEJM 1999.
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.